Maravai raises full-year targets as TriLink mRNA product sales jump 28%
The US supplier of nucleic acid and biologics-safety products posted 10% third-quarter growth, still running at a net loss, and lifted its 2026 revenue and Adjusted EBITDA ranges.
Maravai Lifesciences reported third-quarter 2026 revenue of $45.9m on 4 November, up 10.1% year on year. By our arithmetic, that implies roughly $41.7m in the same quarter of 2025. The company booked a net loss of $24.0m, against Adjusted EBITDA of $5.8m.
The mRNA-related business supplied the standout figure. TriLink, Maravai's nucleic acid production arm, grew revenue 11.8%, and mRNA products within it rose 28%. Cygnus, the company's other reported business, grew 7.5%, so the faster-growing mRNA line was the main driver of the quarter's expansion.
Maravai now guides to 2026 revenue of $212m to $216m and Adjusted EBITDA of $40m to $42m. The material available does not give the earlier ranges, so the size of the increase cannot be stated here. Guidance is a company projection, not an outcome.
The gap between a $24.0m net loss and positive Adjusted EBITDA is not explained in the information available, and nor are the items that separate the two measures. The full results release was not reviewed, so segment revenue in dollars, customer mix and management commentary are not covered.
Why it matters
- A 28% rise in TriLink mRNA product sales suggests demand for mRNA starting materials is holding up for this supplier, though one quarter from one company is a narrow data point.
- Maravai remains loss-making on a net basis even as Adjusted EBITDA is positive. The drivers of that gap are not disclosed in the available material.
- The higher guidance ranges are management's expectations only; the previous ranges were not available, so the scale of the upgrade is unclear.
Company's press release (SEC filing): Maravai Lifesciences Holdings, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
